Midkine: The Who, What, Where, and When of a Promising Neurotrophic Therapy for Perinatal Brain Injury

Midkine (MK) is a small secreted heparin-binding protein highly expressed during embryonic/fetal development which, through interactions with multiple cell surface receptors promotes growth through effects on cell proliferation, migration, and differentiation. MK is upregulated in the adult central...

Descripción completa

Detalles Bibliográficos
Autores principales: Ross-Munro, Emily, Kwa, Faith, Kreiner, Jenny, Khore, Madhavi, Miller, Suzanne L., Tolcos, Mary, Fleiss, Bobbi, Walker, David W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642484/
https://www.ncbi.nlm.nih.gov/pubmed/33193008
http://dx.doi.org/10.3389/fneur.2020.568814
_version_ 1783606095828221952
author Ross-Munro, Emily
Kwa, Faith
Kreiner, Jenny
Khore, Madhavi
Miller, Suzanne L.
Tolcos, Mary
Fleiss, Bobbi
Walker, David W.
author_facet Ross-Munro, Emily
Kwa, Faith
Kreiner, Jenny
Khore, Madhavi
Miller, Suzanne L.
Tolcos, Mary
Fleiss, Bobbi
Walker, David W.
author_sort Ross-Munro, Emily
collection PubMed
description Midkine (MK) is a small secreted heparin-binding protein highly expressed during embryonic/fetal development which, through interactions with multiple cell surface receptors promotes growth through effects on cell proliferation, migration, and differentiation. MK is upregulated in the adult central nervous system (CNS) after multiple types of experimental injury and has neuroprotective and neuroregenerative properties. The potential for MK as a therapy for developmental brain injury is largely unknown. This review discusses what is known of MK's expression and actions in the developing brain, areas for future research, and the potential for using MK as a therapeutic agent to ameliorate the effects of brain damage caused by insults such as birth-related hypoxia and inflammation.
format Online
Article
Text
id pubmed-7642484
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-76424842020-11-13 Midkine: The Who, What, Where, and When of a Promising Neurotrophic Therapy for Perinatal Brain Injury Ross-Munro, Emily Kwa, Faith Kreiner, Jenny Khore, Madhavi Miller, Suzanne L. Tolcos, Mary Fleiss, Bobbi Walker, David W. Front Neurol Neurology Midkine (MK) is a small secreted heparin-binding protein highly expressed during embryonic/fetal development which, through interactions with multiple cell surface receptors promotes growth through effects on cell proliferation, migration, and differentiation. MK is upregulated in the adult central nervous system (CNS) after multiple types of experimental injury and has neuroprotective and neuroregenerative properties. The potential for MK as a therapy for developmental brain injury is largely unknown. This review discusses what is known of MK's expression and actions in the developing brain, areas for future research, and the potential for using MK as a therapeutic agent to ameliorate the effects of brain damage caused by insults such as birth-related hypoxia and inflammation. Frontiers Media S.A. 2020-10-22 /pmc/articles/PMC7642484/ /pubmed/33193008 http://dx.doi.org/10.3389/fneur.2020.568814 Text en Copyright © 2020 Ross-Munro, Kwa, Kreiner, Khore, Miller, Tolcos, Fleiss and Walker. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Ross-Munro, Emily
Kwa, Faith
Kreiner, Jenny
Khore, Madhavi
Miller, Suzanne L.
Tolcos, Mary
Fleiss, Bobbi
Walker, David W.
Midkine: The Who, What, Where, and When of a Promising Neurotrophic Therapy for Perinatal Brain Injury
title Midkine: The Who, What, Where, and When of a Promising Neurotrophic Therapy for Perinatal Brain Injury
title_full Midkine: The Who, What, Where, and When of a Promising Neurotrophic Therapy for Perinatal Brain Injury
title_fullStr Midkine: The Who, What, Where, and When of a Promising Neurotrophic Therapy for Perinatal Brain Injury
title_full_unstemmed Midkine: The Who, What, Where, and When of a Promising Neurotrophic Therapy for Perinatal Brain Injury
title_short Midkine: The Who, What, Where, and When of a Promising Neurotrophic Therapy for Perinatal Brain Injury
title_sort midkine: the who, what, where, and when of a promising neurotrophic therapy for perinatal brain injury
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642484/
https://www.ncbi.nlm.nih.gov/pubmed/33193008
http://dx.doi.org/10.3389/fneur.2020.568814
work_keys_str_mv AT rossmunroemily midkinethewhowhatwhereandwhenofapromisingneurotrophictherapyforperinatalbraininjury
AT kwafaith midkinethewhowhatwhereandwhenofapromisingneurotrophictherapyforperinatalbraininjury
AT kreinerjenny midkinethewhowhatwhereandwhenofapromisingneurotrophictherapyforperinatalbraininjury
AT khoremadhavi midkinethewhowhatwhereandwhenofapromisingneurotrophictherapyforperinatalbraininjury
AT millersuzannel midkinethewhowhatwhereandwhenofapromisingneurotrophictherapyforperinatalbraininjury
AT tolcosmary midkinethewhowhatwhereandwhenofapromisingneurotrophictherapyforperinatalbraininjury
AT fleissbobbi midkinethewhowhatwhereandwhenofapromisingneurotrophictherapyforperinatalbraininjury
AT walkerdavidw midkinethewhowhatwhereandwhenofapromisingneurotrophictherapyforperinatalbraininjury

Ejemplares similares